1
|
McDermott RL, Mihai A, Dunne M, Keys M, O'Sullivan S, Thirion P, ElBeltagi N, Armstrong JG. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma. Clin Oncol (R Coll Radiol) 2020; 33:292-299. [PMID: 33309479 DOI: 10.1016/j.clon.2020.11.026] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Revised: 10/28/2020] [Accepted: 11/25/2020] [Indexed: 12/25/2022]
Abstract
AIMS Stereotactic ablative radiation therapy (SABR) is a standard of care for medically inoperable early stage non-small cell lung carcinoma. Tumours greater than 5 cm have been excluded from randomised trials using SABR and, hence, it is not used as a standard for larger lung tumours. However, improvements in radiation therapy techniques and the success of SABR in treatment of early stage disease may allow safe delivery of ablative doses to larger tumours. We analysed our experience with tumours ≥5 cm to determine the efficacy and toxicity profile of SABR in this setting. MATERIALS AND METHODS We evaluated survival, control rates, patterns of failure and toxicity in patients with a tumour diameter larger than 5 cm that had no nodal or distant metastases treated with SABR technology. Patients had been treated in two centres since 2009 and were retrospectively analysed. All patients had positron emission tomography staging, were discussed at a tumour board and were documented to have no nodal or distant metastatic disease. Treatment outcomes were analysed using Kaplan-Meier estimates and compared using the Log-rank test. Cox regression was used to investigate the association between the survival outcomes and predictor variables. RESULTS In total, 86 patients were identified. Six patients had no follow-up imaging. Therefore, 80 patients were available for analysis. All patients were reclassified according to the updated AJCC eighth edition. The median follow-up was 19.6 months. No patients received neoadjuvant or concurrent systemic therapy. One patient received adjuvant systemic therapy. The median age at treatment was 77 years (range 58-91). Eighty-four per cent were stage T3N0M0 and 16% were staged T4N0M0. The median tumour diameter was 5.8 cm (range 5.0-9.3 cm). The median gross tumour volume, measured on a single phase of the respiratory cycle, was 45.7 cm3 (range 12.1-203.3 cm3). The median overall survival was 20.9 months (95% confidence interval 12.6-29.1 months). One-, 2- and 3-year overall survival was 71%, 48% and 32%, respectively. The median local failure-free survival was 19.5 months (95% confidence interval 14.4-24.6). The median disease-free survival was 15.1 months (95% confidence interval 9.9-20.4 months). Local control at 1, 2 and 3 years was 85% (95% confidence interval 76-94%), 71% (95% confidence interval 58-84%) and 57% (95% confidence interval 40-74%), respectively. Forty-four patients (55%) had any treatment failure (local, mediastinal, intrapulmonary or distant metastases). Out-of-field intrapulmonary disease progression was the most common mode of failure, occurring in 21 patients (26%). Local failure occurred in 19 patients (24%) - alone or in combination with other progression. Distant metastases occurred in 20 patients (25%). Neither histological subtype, tumour size nor gross tumour volume had a statistically significant effect on local failure-free survival. Two patients experienced grade 3 late dyspnoea. There were no other reported grade 3 or higher acute or late toxicities. CONCLUSION SABR for larger lung tumours ≥5 cm results in high local control and acceptable survival in patients with medically inoperable large non-small cell lung carcinoma treated with radiation alone. Such patients should be considered for SABR owing to fewer treatment fractions and acceptable toxicity. Local control analysis reveals a sustained pattern of local failure emphasising the need for long-term follow-up. Improvements in technical strategies are required to further improve local control.
Collapse
Affiliation(s)
- R L McDermott
- St Luke's Institute of Cancer Research, Rathgar, Dublin, Ireland; St Luke's Radiation Oncology Network, St Luke's Hospital, Rathgar, Dublin, Ireland.
| | - A Mihai
- Beacon Hospital, Sandyford, Dublin, Ireland
| | - M Dunne
- St Luke's Radiation Oncology Network, St Luke's Hospital, Rathgar, Dublin, Ireland
| | - M Keys
- St Luke's Radiation Oncology Network, St Luke's Hospital, Rathgar, Dublin, Ireland; St Luke's Radiation Oncology Network, St James' Hospital, Dublin, Ireland
| | - S O'Sullivan
- St Luke's Institute of Cancer Research, Rathgar, Dublin, Ireland; St Luke's Radiation Oncology Network, St Luke's Hospital, Rathgar, Dublin, Ireland
| | - P Thirion
- Beacon Hospital, Sandyford, Dublin, Ireland; St Luke's Radiation Oncology Network, St James' Hospital, Dublin, Ireland
| | - N ElBeltagi
- St Luke's Radiation Oncology Network, St Luke's Hospital, Rathgar, Dublin, Ireland
| | - J G Armstrong
- St Luke's Institute of Cancer Research, Rathgar, Dublin, Ireland; St Luke's Radiation Oncology Network, St Luke's Hospital, Rathgar, Dublin, Ireland; St Luke's Radiation Oncology Network, St James' Hospital, Dublin, Ireland
| |
Collapse
|
2
|
McDermott RL, Hutchinson B, Ryan C, Conneely JB, Latif A, Maguire D, Sheahan K. Mesenteric lipodystrophy - An unusual intraabdominal mass. Int J Surg Case Rep 2013; 4:232-4. [PMID: 23291330 DOI: 10.1016/j.ijscr.2012.11.024] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2012] [Revised: 11/23/2012] [Accepted: 11/23/2012] [Indexed: 11/19/2022] Open
Abstract
INTRODUCTION We report the case of a 21 year old female with underlying facial lipodystrophy who presented with left lower abdominal pain, weight gain and altered bowel habit. PRESENTATION OF CASE Subsequent investigation showed a large (21cm×18cm×8cm) intraabdominal mass. At laparotomy, it was completely excised and was seen to arise from the transverse mesocolon and following histology revealed it to be mesenteric lipodystrophy. DISCUSSION Mesenteric lipodystrophy is a rare clinical entity, and part of a spectrum of disorders of sclerosing mesenteritis. This is the first reported case in a patient with pre-existing facial lipodystrophy. CONCLUSION Herein we describe a case of mesenteric lipodystrophy, discuss its management and review of the literature.
Collapse
Affiliation(s)
- R L McDermott
- Department of General and Hepatopbiliary Surgery, St. Vincent's University Hospital, Elm Park, Dublin 4, Ireland.
| | | | | | | | | | | | | |
Collapse
|
3
|
Sprengelmeyer JT, McDermott RL. Phosphorus-32-colloidal chromic phosphate: treatment of choice for malignant pericardial effusion. J Nucl Med 1990; 31:2034-6. [PMID: 2266403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
A 68-yr-old male with agnogenic myeloid metaplasia was given phosphorus-32-colloidal chromic phosphate intrapericardially for the treatment of malignant pericardial effusion. Technetium-99m-sulfur colloid was used to verify catheter placement and to visualize distribution within the pericardium. Estimated dosimetry for this mode of therapy is presented, and it is suggested that pericardial administration of phosphorus-32-colloidal chromic phosphate is the treatment of choice for malignant pericardial effusion.
Collapse
Affiliation(s)
- J T Sprengelmeyer
- Nuclear Medicine Dept., Kaiser Foundation Hospital, West Los Angeles, CA 90034
| | | |
Collapse
|